In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer's Exubera: Breathing New Life Into Inhaled Insulin

Executive Summary

Dragging a host of safety concerns, Exubera hardly inspired confidence when it went before an FDA advisory committee. But Pfizer proposed an aggressive risk management scheme that won it a dramatic "yes" vote. How one company addressed a drug's safety concerns head-on to win the confidence of FDA's advisors.

Related Content

Insulin Delivery: Still Waiting to Exhale
Pyramid Schemes and Pipeline Dreams: Adapting to a Tiered Regulatory System for New Drugs
The Death of Arcoxia: Drug Regulation in a "Whistleblower" Climate
Advances in Diabetes Management
Map To FDA RiskMAPs
Lost in Translation: Interpreting Advisory Committees
Inhaled Insulin: Being First Isn't Necessarily Best
Exubera in 2006?
Big Pharma's Large Molecule Challenge


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts